Filing Flows › Rhythm Pharmaceuticals (RYTM) › Q2 2026
Rhythm Pharmaceuticals (RYTM) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 4, 2026
Rhythm Pharmaceuticals (RYTM) reported revenue of $71.3M for the second quarter 2026 (Q2 2026), +47% from a year earlier and +19% from the quarter before. Operating margin was -68.1%, net loss $49.3M (69.2% of revenue).
Rhythm Pharmaceuticals, Q2 2026: revenue $71.3M (+47% year over year), operating margin -68.1%, net loss $49.3M, operating cash flow −$9.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $71.3M | +19% | +47% |
| Operating profit | −$48.6M | — | — |
| Net earnings | −$49.3M | — | — |
| Operating cash flow | −$9.2M | — | — |
What changed
Revenue was $71.3M in Q2 2026, up 47% year over year and up 19% from the previous quarter.
Operating costs exceeded revenue by $48.6M, an operating margin of -68.1%. Total costs grew 28% against revenue growth of 47%. The fastest-growing cost line was Cost of revenue (+61%). The quarter ended with a net loss of $49.3M, narrower than the previous quarter's $55.6M loss.
Operating cash flow was −$9.2M. Non-cash charges added back $26.1M of share-based compensation. Working capital and other items added $14.1M.
Questions
What was Rhythm Pharmaceuticals' revenue in the second quarter 2026?
Rhythm Pharmaceuticals (RYTM) reported revenue of $71.3M for the second quarter 2026 (Q2 2026), +47% from a year earlier and +19% from the quarter before.
Was Rhythm Pharmaceuticals profitable in the second quarter 2026?
Operating loss was $48.6M (-68.1% of revenue) and net loss $49.3M.